The Effect of Three Desensitizing Agents on Dentin Hypersensitivity: A Randomized, Split-mouth Clinical Trial

SUMMARY The aim of this study was to evaluate the efficacy of three desensitizing agents to provide relief to dentin hypersensitivity after one session in a four-week follow-up. Forty selected patients participated in a double-blind study following a split-mouth model. One application of the desensitizing agents (A, Admira Protect [Voco]; B, Bifluorid 12 [Voco]; and C, Colgate Pro-Relief in office [Colgate Palmolive]) was performed in three different quadrants for each patient. Each tooth was evaluated by tactile and evaporative stimuli, and the sensitivity response was measured using the Visual Analogue Scale. Evaluations were performed at baseline, immediately after treatment, and after one, two, three, and four weeks. The application of Kruskal-Wallis and Dunn multiple comparisons tests (5%) for both tactile and evaporative stimuli showed that all agents presented a significant desensitizing effect. In groups A and B this relief was maintained for four and three weeks, respectively, as measured by tactile stimulus and for four weeks with evaporative stimulus. The desensitizing effect for group C was maintained for two weeks for both tactile and evaporative stimuli. It is concluded that all desensitizing agents tested were effective in reducing sensitivity compared to baseline values. One application of Admira Protect and Bifluorid 12 presented a longer-lasting desensitizing effect than did Colgate Pro-Relief (applied in the office) on both tactile and evaporative stimuli.

Download Full-text

Efficacy of SEBCLAIRA® Cream for Moderate Seborrhoeic Dermatitis on The Face as An Adjuvant Therapy (Randomised Clinical Trial, Double Blind)

BioScientia Medicina ◽

10.32539/bsm.v2i2.47 ◽

2018 ◽

Vol 2 (2) ◽

pp. 54-60

Author(s):

Inda Astri Aryani ◽

Yulia Farida Yahya ◽

Nina Roiana ◽

Radema A Pranata

Keyword(s):

Clinical Trial ◽

Analogue Scale ◽

Calcineurin Inhibitor ◽

Severity Index ◽

Randomised Clinical Trial ◽

Double Blind Study ◽

Double Blind ◽

Seborrhoeic Dermatitis ◽

The Face ◽

The Mean

Background: Seborrhoeic dermatitis (SD) is a chronic papulosquamous inflammatory disease which resistant to medical treatment. Various treatment such as topical corticosteroid, antifungal and calcineurin inhibitor has been widely practiced and gives varying results Objective: Our objective was to compare the efficacy of Sebclaira® and topical hydrocortisone 2,5% for management of moderate SD on the face Methods: A randomised clinical trial, controlled, double blind study was performed for four weeks. We assessed the efficacy and side effects of these topical treatment. The severity of SD was evaluated using Seborrhea Area Severity Index-Facial (SASI-F) score. The severity of pruritus was evaluated using Visual Analogue Scale. Demographic characteristics, baseline SASI-F and VAS were recorded in the medical record. Results: A 34 patients (14 males, 20 females) with moderate SD on the face completed the four weeks study. The mean of SASI T2 and VAS score of the Sebclaira® group was significantly lower than Hydrocortisone 2.5% group with p = 0.000 and p = 0.000 respectively. Tolerance between Sebclaira® and Hydrocortisone 2.5% showed insignificant results (p = 1.000) Conclusions: The longer application of Sebclaira® was significantly more effective to improve moderate SD

Download Full-text

Arnica/Hydroxyethyl Salicylate Combination Spray for Ankle Distortion: A Four-Arm Randomised Double-Blind Study

Pain Research and Treatment ◽

10.1155/2011/365625 ◽

2011 ◽

Vol 2011 ◽

pp. 1-7 ◽

Cited By ~ 1

Author(s):

Miroslav Kučera ◽

Pavel Kolar ◽

Milos Barna ◽

Alexander Kučera ◽

Marie Hladiková

Keyword(s):

Analogue Scale ◽

Cumulative Effect ◽

Double Blind Study ◽

Additive Effects ◽

Double Blind ◽

Active Constituents ◽

Treatment Groups ◽

Group A ◽

Baseline Values ◽

Pain Improvement

570 patients with acute ankle joint distortion were randomized to four treatment groups: a combination spray of arnica tincture and hydroxyethyl salicylate (HES; group A, ), arnica (B, ), HES (C, ), and placebo (D, ). The medication was applied 4-5 times daily for 10 days. Efficacy was assessed on day 3-4 by evaluating pain on motion on a visual analogue scale (VAS). Pain improvement in group A was significantly superior over groups B–D (-test with unadjusted baseline values, and ANCOVA after adjustment, ) and approximately corresponded to the cumulative effect of the single constituents (12.1, 7.5, and 18.7 mm VAS for A versus B, A versus C, and A versus D; 95% CI 8.0–16.2, 4.7–10.4, and 14.8–22.5 mm). The combination is justified by the additive effects of the single active constituents.

Download Full-text

Dentin hypersensitivity after treatment with desensitizing agents: a randomized, double-blind, split-mouth clinical trial

Brazilian Dental Journal ◽

10.1590/s0103-64402011000200012 ◽

2011 ◽

Vol 22 (2) ◽

pp. 157-161 ◽

Cited By ~ 11

Author(s):

Jorgiana Silva de Assis ◽

Lidiany Karla Azevedo Rodrigues ◽

Cristiane Sá Roriz Fonteles ◽

Regina Cláudia Ramos Colares ◽

André Mattos Brito de Souza ◽

...

Keyword(s):

Clinical Trial ◽

T Test ◽

The Other ◽

Dentin Hypersensitivity ◽

Double Blind ◽

Desensitizing Agents ◽

Paired T Test

The aim of this study was to evaluate the efficacy of two desensitizing agents in the reduction of dentin hypersensitivity in a randomized, double-blind, split-mouth clinical trial. Seventy-seven teeth from 13 patients that presented some degree of sensitivity to probing and/or air stimulation were treated with one of the following desensitizing agents: Oxa-Gel (G1), Sensi Kill (G2) and placebo gel (G3 - control). According to paired t-test, all treatments, even the placebo gel, were capable of reducing sensitivity scores for both stimuli. Analysis of data by ANOVA and Tukey's test (?=0.05) showed that the sensitivity scores were significantly lower only for Sensi Kill in comparison to the other products (Oxa-Gel and placebo), when air stimulus was applied. It may be concluded that treatment with Sensi Kill presented a slightly better performance in reducing dentin hypersensitivity when compared to the other desensitizing agent.

Download Full-text

Phase III Clinical Trial Comparing Iopamidol 250 mgI/mL and Iopamidol 300mgI/mL in Cerebral Angiography: Multicenteric, Randomized and Double Blind Study

Journal of the Korean Radiological Society ◽

10.3348/jkrs.2007.57.6.501 ◽

2007 ◽

Vol 57 (6) ◽

pp. 501

Author(s):

Hyobin Seo ◽

Moon Hee Han ◽

Bae Ju Kwon ◽

So Hyang Im ◽

Cheolkyu Jung ◽

...

Keyword(s):

Clinical Trial ◽

Cerebral Angiography ◽

Blind Study ◽

Phase Iii ◽

Double Blind Study ◽

Double Blind ◽

Phase Iii Clinical Trial

Download Full-text

Low-Level Laser and Light-Emitting Diode Therapy for Pain Control in Hyperglycemic and Normoglycemic Patients Who Underwent Coronary Bypass Surgery with Internal Mammary Artery Grafts: A Randomized, Double-Blind Study with Follow-Up

Photomedicine and Laser Surgery ◽

10.1089/pho.2015.4049 ◽

2016 ◽

Vol 34 (6) ◽

pp. 244-251 ◽

Cited By ~ 8

Author(s):

Andréa Conceição Gomes Lima ◽

Gilderlene Alves Fernandes ◽

Isabel Clarisse Gonzaga ◽

Raimundo de Barros Araújo ◽

Rauirys Alencar de Oliveira ◽

...

Keyword(s):

Bypass Surgery ◽

Internal Mammary Artery ◽

Light Emitting Diode ◽

Coronary Bypass ◽

Double Blind Study ◽

Double Blind ◽

Light Emitting ◽

Level Laser ◽

Internal Mammary

Download Full-text

Sulphadiazine/Trimethoprim Once Daily in Maxillary Sinusitis: A Randomized Double-Blind Comparison with Sulphamethoxazole/Trimethoprim B.I.D.

Journal of International Medical Research ◽

10.1177/030006058100900609 ◽

1981 ◽

Vol 9 (6) ◽

pp. 478-481 ◽

Cited By ~ 1

Author(s):

Pierre Federspil ◽

Peter Bamberg

Keyword(s):

Maxillary Sinusitis ◽

Favourable Result ◽

Double Blind Study ◽

Double Blind ◽

Once Daily ◽

Days Of Therapy ◽

Significant Difference ◽

Blind Comparison ◽

Cure Rates

In a randomized double-blind study fifty-four patients suffering from acute maxillary sinusitis were treated for 10 days with daily doses of sulphadiazine/trimethopim (1 g) and sulphamethoxazole/trimethoprim (1.92 g), respectively. The efficacy was evaluated clinically at two follow-up visits. X-ray investigations were performed at admission and after the therapy. Of thirty-nine patients finally evaluated, thirty-seven showed a favourable result. After 6–8 days of therapy there was significant difference in cure rates in favour of sulphadiazine/trimethoprim (p < 0.05) while the outcome as evaluated after treatment was similar for both drugs.

Download Full-text

The long-term effects of homeopathic treatment of chronic headaches: one year follow-up and single case time series analysis

British Homeopathic Journal ◽

10.1054/homp.1999.0473 ◽

2001 ◽

Vol 90 (02) ◽

pp. 63-72 ◽

Cited By ~ 17

Author(s):

H Walach ◽

T Lowes ◽

D Mussbach ◽

U Schamell ◽

W Springer ◽

...

Keyword(s):

Time Series ◽

Single Case ◽

Double Blind Study ◽

Long Term Effects ◽

Double Blind ◽

Homeopathic Treatment ◽

Chronic Headaches ◽

One Year

AbstractLittle is known about long-term effects of homeopathic treatment. Following a double-blind, placebo controlled trial of classical homeopathy in chronic headaches, we conducted a 1-year observational study of 18 patients following the double-blind phase, and a complete follow-up study of all trial participants. Eighteen patients received free treatment for daily diary data (frequency, intensity, duration of headaches) over the course of 1 y. All patients enrolled in the double-blind study were sent a 6-week headache diary, a follow-up questionnaire, a personality inventory and a complaint list. Eighty-seven, of the original 98 patients enrolled returned questionnaires, 81 returned diaries. There was no additional change from the end of the trial to the one-year follow-up. The improvement seen at the end of the 12-week trial was stable after 1 y. No differential effects according to treatment after the trial could be seen. Patients with no treatment following the trial had the most improvement after 1 y. Five of 18 patients can be counted responders according to ARIMA analysis of single-case time-series. Patients with double diagnoses and longer treatment duration tended to have clearer improvements than the rest of the patients. Approximately 30% of patients in homeopathic treatment will benefit after 1 y of treatment. There is no indication of a specific, or of a delayed effect of homeopathy.

Download Full-text